Association analysis of the 5-HT(5A) gene in depression, psychosis and antipsychotic response

NeuroReport

Volumn 11, Issue 9, 2000, Pages 2017-2020

  Birkett, Joseph T ^a   Arranz, Maria J ^a   Munro, Janet ^a   Osbourn, Sarah ^a   Kerwin, Robert W ^a   Collier, David A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atypical neuroleptics; Neurotransmitter receptor; Pharmacogenetics; Psychosis; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; NEUROLEPTIC AGENT; SEROTONIN;

AFFECTIVE NEUROSIS; ALLELE; ARTICLE; CONTROLLED STUDY; DEPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

EID: 0012820694     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200006260-00042     Document Type: Article

References (28)

1. 1. Cardno AG, Marshall EJ, Coid B et al. Arch Gen Psychiatry 56, 162-168 (1999).
2. 2. Craddock N and Jones I. J Med Genet 36, 585-594 (1999).
3. 3. Bierut LJ, Heath AC, Bucholz KK et al. Arch Gen Psychiatry 6, 557-563 (1999).
4. 4. Foley DL, Neale MC and Kendler KS. Psychol Med 28, 857-870 (1998).
5. 5. McGuffin P, Katz R, Watkins S and Rutherford J. Arch Gen Psychiatry 53, 129-36 (1996).
6. 6. Riley BP and McGuffin P, Submitted (2000).
7. 7. Owens MJ and Nemeroff CB. Clin Chem 40, 288-295 (1994).
8. 8. Jacobs BL and Fornal CA. Physiology and pharmacology of brain serotonergic neurons. In: Baumgarten HG and Gothert M, eds. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer Verlag, 1997: 175-212.
9. 9. Meltzer HY. Neuropsychopharmacology 21,106S-115S (1999).
10. 10. Kerwin RW. Br J Psychiatry 164, 141-148 (1994).
11. 11. Westenberg HG. J Clin Psychiatry 60 Suppl 17, 4-8 (1999).
12. 12. Delgado PL, Price LH, Miller HL et al. Arch Gen Psychiatry 51, 865-874 (1994).
13. 13. Smith KA, Fairburn CG and Cowen PJ. Lancet 349, 915-919 (1997).
14. 14. Leyton M, Young SN and Benkelfat C. Lancet 349, 1840-1841 (1997).
15. 15. Nishizawa S, Benkelfat C, Young SN et al. Proc Natl Acad Sci USA 94, 5308-5313 (1997).
16. 16. Fink G, Sumner BE, McQueen JK et al. Clin Exp Pharmacol Physiol 1998 25, 764-775 (1998).
17. 17. Nair NP and Sharma M. Psychiat J Univ Ottawa 14, 328-341 (1989).
18. 18. Risch SC and Nemeroff CB. J Clin Psychiatry Suppl., 3-7 (1992).
19. 19. Francis PT, Pangalos MN, Stephens PH et al. J Neurol Neurosurg Psychiatry 56, 80-84 (1993).
20. 20. Young LT, Warsh JJ, Kish SJ et al. Biol Psychiatry 35, 121-127 (1994).
21. 21. Ohuoha DC, Hyde TM and Kleinman JE. Psychopharmacology (Berl) 112, S5-S15 (1993).
22. 22. Sipes TA and Geyer MA. Neuropharmacology 33, 441-448 (1994).
23. 23. Pasqualetti M, Ori M, Marazziti D et al. Ann NY Acad Sci 861, 245 (1998).
24. 24. Waeber C, Grailhe R, Yu XJ et al. Ann NY Acad Sci 861, 85-90 (1998).
25. 25. Carson MJ, Thomas EA, Danielson PE and Sutcliffe JG. Glia 17, 317-326 (1996).
26. 26. Rees S, den Daas I, Foord S et al. FEBS Lett 355, 242-246 (1994).
27. 27. Shimron-Abarbanell D, Erdmann J, Vogt IR et al. Biochem Biophys Res Commun 283, 6-9 (1997).
28. 28. Iwata N, Virkkunen M, Linnoila M and Goldman D. Brain Res Mol Brain Res 58, 217-220 (1998).